MARLBOROUGH, Mass.--(BUSINESS WIRE)--Sepracor Inc. today announced that clinical study data for STEDESA™ (eslicarbazepine acetate; ESL) were presented during a scientific poster session at the 2009 annual meeting of the American Epilepsy Society (AES) in Boston. Seven posters were presented on Dec. 5, 2009 and included data regarding safety and efficacy evaluations of STEDESA. These data were derived from the pooled results of three, placebo-controlled Phase III studies of STEDESA in which adult patients who had a history of at least four partial-onset seizures per month despite treatment with one to three concomitant antiepileptic drugs (AEDs) were randomized to 400 mg, 800 mg or 1200 mg of ESL or placebo.
